Kisspeptin dosage: Frequently asked questions

Verify three variables before adjusting dose: (1) peptide purity and reconstitution concentration, (2) timing relative to endogenous GnRH pulse cycle, and (3) subject's baseline gonadotropin status. Blunted LH response in subjects with pre-existing hypothalamic suppression (low baseline LH <1.5 IU/L) is common. GnRH neurons require 'priming' with lower kisspeptin doses (0.24 nmol/kg daily for three days) before full responsiveness returns. If baseline LH is normal (>2.0 IU/L) but response remains subthreshold, suspect peptide degradation or dosing during the refractory period immediately post-endogenous pulse.

Mild erythema at the injection site within 30 minutes post-administration is common and typically resolves within two hours without intervention. It reflects localised histamine release rather than infection or allergic reaction. Persistent redness beyond four hours, induration, or spreading erythema warrants discontinuation and consultation. These signs suggest either contamination during reconstitution or hypersensitivity to residual synthesis reagents (acetate salts, TFA traces) present in lower-purity peptide batches.

This indicates GPR54 receptor desensitisation. A well-documented phenomenon when kisspeptin dosing intervals fall below 60 minutes or when supraphysiological doses (>4.0 nmol/kg subcutaneous) are used repeatedly. Receptor recycling requires 90–120 minutes, and chronic high-dose exposure downregulates GPR54 expression at the transcriptional level within 48 hours. The solution is extending the dosing interval to ≥90 minutes and reducing dose to the minimum effective threshold (0.5–1.0 nmol/kg for most reproductive endpoints).

Discard it immediately. Do not attempt to use it. Kisspeptin-10 undergoes irreversible structural denaturation at temperatures above 8°C, with degradation rate doubling every 3°C increase above refrigeration threshold. A vial left at 22°C for eight hours loses approximately 35–50% of bioactive peptide as measured by HPLC, and what remains may contain aggregated protein fragments that trigger immune responses without producing GPR54 activation. Reconstituted peptides tolerate brief ambient exposure (<30 minutes during preparation), but overnight temperature excursions cannot be salvaged.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Subcutaneous pulsatile protocols using 1.0–3.0 nmol/kg every 90 minutes for 24–48 hours successfully override endogenous GnRH pulsatility in hypothalamic amenorrhea models. Prepare individual syringes in advance and refrigerate at 2–8°C. Reconstituted kisspeptin-54 in bacteriostatic water remains stable for 7 days under refrigeration. Administer via insulin syringe into alternating subcutaneous sites (abdomen, thigh) to avoid injection-site peptidase saturation. Monitor for tachyphylaxis after 48 hours. Continuous kisspeptin exposure can begin desensitising pituitary GnRH receptors, shifting the response curve downward.

Natural preovulatory LH surges result from sustained hypothalamic kisspeptin secretion over 12–24 hours, not a single pharmacological pulse. Replicating that requires either continuous infusion (0.04–0.06 nmol/kg/hour for 18–24 hours) or escalating pulsatile doses (starting at 0.5 nmol/kg SC, increasing to 1.2 nmol/kg at 6-hour intervals). Research from Massachusetts General Hospital demonstrated that 24-hour kisspeptin infusion at 0.048 nmol/kg/hour produced LH profiles nearly identical to natural mid-cycle surges in healthy women, with peak LH reaching 35–50 IU/L. Single boluses cannot achieve this because LH secretion depends on sustained GPR54 activation, not peak kisspeptin concentration.

Check your reconstitution and storage first. Kisspeptin peptides degrade rapidly at temperatures above 8°C. If your lyophilised powder was stored improperly or reconstituted with non-bacteriostatic water, structural integrity is compromised and LH-stimulating activity is lost. Assuming peptide integrity is intact, a blunted response at 2.5 nmol/kg suggests prior receptor desensitisation from recent kisspeptin administration (within the past 6 hours), baseline hypogonadotropic state (low endogenous GnRH tone reducing pituitary responsiveness), or incorrect dosing calculations. Verify your body weight-based dose conversion and confirm the peptide concentration in your reconstituted solution matches expected values.

Obesity-associated leptin resistance and chronic low-grade inflammation reduce hypothalamic kisspeptin sensitivity. Ob/ob mice require 2–3× higher kisspeptin doses to achieve equivalent GnRH stimulation compared to lean controls. A 2018 study in diet-induced obese rats found that the ED50 for LH stimulation shifted from 0.5 nmol/kg in lean animals to 1.8 nmol/kg in obese cohorts. If you're modelling metabolic hypogonadism, expect to re-establish dose-response curves rather than applying lean-model doses directly. Leptin co-administration (where applicable) can partially restore kisspeptin sensitivity, reducing the required dose by 30–40%.

Stop kisspeptin administration for 48–72 hours to allow GPR54 receptor recycling. Beta-arrestin-mediated internalization reverses within 2–3 days of agonist withdrawal. Surface receptor density returns to 85–95% of baseline. If stopping isn't feasible, reduce pulse frequency from every 60 minutes to every 120 minutes and lower dose per pulse by 30–40%. Studies using a 'washout period' every 3–4 days in chronic kisspeptin protocols maintained LH responsiveness over 28 days, while continuous dosing without breaks showed progressive blunting.

Increase dose to 10–15 nmol/kg and verify injection depth. Shallow SC injections into adipose tissue (especially in models with higher body fat) slow absorption further. Aim for deeper SC placement into the subcutaneous layer overlying muscle fascia. If LH response remains blunted after dose escalation, consider IV administration or switch to kisspeptin-54 instead of kisspeptin-10. The longer peptide shows slightly better SC bioavailability in some studies, though the mechanism isn't fully understood.

Administer the dose as planned, but do not expect equivalent central effects. Subcutaneous kisspeptin undergoes hepatic first-pass degradation that reduces bioavailability by 60–70% compared to IV bolus. A 1 nmol/kg subcutaneous dose delivers approximately 0.3–0.4 nmol/kg to systemic circulation. You will observe peripheral gonadotropin elevation (LH surge within 90–180 minutes), but limbic activation and subjective libido enhancement are unlikely unless the subcutaneous dose is scaled to ≥50 mcg. If central effects are the research objective, switch to IV administration or use intranasal delivery if blood-brain barrier penetration is critical.

Single boluses won't achieve this. LH returns to baseline within 2–4 hours regardless of dose. The protocol that maintains sustained LH elevation is continuous IV infusion at 0.02–0.05 nmol/kg/hour, which keeps plasma kisspeptin concentrations above the threshold for GPR54 activation without saturating receptors. Alternatively, subcutaneous pulsatile dosing (0.6–0.8 nmol/kg every 4 hours) mimics endogenous ultradian LH pulsatility. Both approaches prevent receptor downregulation while maintaining LH secretion across extended timeframes. The mechanism underlying experimental kisspeptin therapy for functional hypothalamic amenorrhea.

This is the expected outcome with subcutaneous or low-dose IV protocols. Kisspeptin drives LH release via pituitary KISS1R activation. A peripheral mechanism that does not require CNS penetration. Central libido enhancement requires activation of limbic KISS1R receptors in the hypothalamus, thalamus, and posterior cingulate cortex, which only occurs when intact peptide crosses the blood-brain barrier at sufficient concentrations. If LH is elevated but libido is unchanged, the protocol successfully targeted the reproductive axis but failed to achieve central pharmacological activity. Increase the IV dose to 2.0 nmol/kg or switch to continuous infusion to maintain CNS concentrations above the activation threshold.

Administer it if the exposure was brief (≤48 hours), but verify potency if stored longer. Lyophilised kisspeptin-10 is stable at room temperature for 24–48 hours, but extended ambient storage (>72 hours) causes peptide degradation that HPLC cannot always detect without specific analysis. Kisspeptin's C-terminal amidation is vulnerable to hydrolysis at temperatures above 25°C. Once degraded, the peptide loses KISS1R binding affinity entirely. If the vial was stored at room temperature for more than 72 hours before reconstitution, discard it and use properly stored inventory. Unreliable potency creates null results that waste research time and subject participation.

Administer as pulsatile boluses every 90 minutes rather than a single daily dose. A single daily injection. Even at high doses like 10 nmol/kg SC. Produces a transient LH spike that returns to baseline within 4–6 hours due to kisspeptin's 30-minute half-life. The HPG axis requires sustained GnRH signaling to maintain elevated LH and testosterone, which means either continuous low-dose infusion (which causes receptor desensitization) or repeated pulses throughout the day. Research using once-daily kisspeptin showed LH elevation lasted only until the next circadian trough, with no cumulative testosterone increase over 7 days.

Verify three variables before escalating dose: peptide purity (request HPLC and mass spectrometry from your supplier), administration timing relative to endogenous LH pulses (measure baseline LH every 10 minutes for 2 hours before dosing), and route bioavailability correction (confirm whether the published study used IV or SC and adjust accordingly). A 2014 replication study found that 40% of dose-response inconsistencies traced to unverified peptide degradation during storage. Lyophilised kisspeptin stored above −20°C loses 15–25% binding affinity within 60 days even without visible degradation.

Increase your reconstitution volume to lower the final concentration. If 5mg kisspeptin reconstituted in 2mL produces 2500µg/mL and your 250µg dose requires 0.10mL (10 units), that fits within a standard 0.3mL or 0.5mL insulin syringe. But if you're using a 0.3mL syringe and need 0.12mL per injection, you're at 40% of syringe capacity. Any measurement error is magnified. Reconstitute the same 5mg in 5mL instead to produce 1000µg/mL concentration, where 250µg requires 0.25mL (25 units). Larger volumes reduce relative measurement error.

Assume 95% purity and calculate dosage using 4.75mg as the corrected peptide mass. This is the conservative standard when purity data is unavailable. It prevents overdosing while staying within typical research-grade peptide purity ranges. Contact your supplier immediately to request the CoA, and if they cannot provide HPLC verification, consider switching to a supplier that includes third-party purity testing with every batch. Peptide quality without documentation is not quality.

Recalculate concentration using the actual volume added and proceed with the corrected math. If 5mg kisspeptin was diluted in 2.2mL instead of 2.0mL, the concentration is now 2273µg/mL instead of 2500µg/mL. A 100µg dose requires 0.044mL (4.4 units) instead of 0.04mL (4 units). Do not attempt to remove excess liquid from the vial. Bacteriostatic water removal risks contamination and changes concentration unpredictably. The vial is still usable; the math just needs adjustment.